Shifting paradigms: The central role of microglia in Alzheimer's disease

• Published in: Neurobiology of disease Vol. 143; p. 104962
• Main Authors: Schwabe, Tina, Srinivasan, Karpagam, Rhinn, Herve
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2020; Elsevier
• Subjects: ABCA7; Alzheimer's disease; APOE; Brain; CD33; GWAS; Microglia; MS4A4A; MS4A6A; Neurodegeneration; Neuropathology; Single-cell; Single-nuclei; Transcriptomic; TREM2; Brain; GWAS; Neuropathology; TREM2; ABCA7; Single-cell; Microglia; MS4A4A; MS4A6A; Single-nuclei; Neurodegeneration; APOE; Transcriptomic; Alzheimer's disease; CD33
• ISSN: 0969-9961; 1095-953X
• DOI: 10.1016/j.nbd.2020.104962

Recent human genetic studies have challenged long standing hypotheses about the chain of events in Alzheimer's disease (AD), as the identification of genetic risk factors in microglial genes supports a causative role for microglia in the disease. Parallel transcriptome and histology studies at the single-cell level revealed a rich palette of microglial states affected by disease status and genetic risk factors. Taken together, those findings support microglia dysfunction as a central mechanism in AD etiology and thus the therapeutic potential of modulating microglial activity for AD treatment. Here we review how human genetic studies discovered microglial AD risk genes, such as TREM2, CD33, MS4A and APOE, and how experimental studies are beginning to decipher the cellular functions of some of these genes. Our review also focuses on recent transcriptomic studies of human microglia from postmortem tissue to critically assess areas of similarity and dissimilarity between human and mouse models currently in use in order to better understand the biology of innate immunity in AD.